Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial - PubMed
5 hours ago
- #diabetes
- #cardiorenal outcomes
- #tirzepatide
- Tirzepatide showed a lower incidence of a 6-component composite cardiorenal outcome compared to dulaglutide in patients with type 2 diabetes and cardiovascular disease.
- The primary endpoint included all-cause mortality, MI, stroke, coronary revascularization, hospitalization for heart failure, and adverse kidney outcomes, with a hazard ratio of 0.84 favoring tirzepatide.
- Gastrointestinal adverse events were more common with tirzepatide than dulaglutide, but other adverse events were similar between the treatments.